Schedule II & RFK ·
Since taking office as HHS Secretary in early 2025, RFK Jr. has made several public statements about peptides, compounded medications, and FDA regulatory approach. In a February 2025 Joe Rogan Experience appearance he discussed peptide therapy in the context of chronic disease and longevity research. In a televised March 2026 town hall, RFK Jr. reiterated a view that US regulatory frameworks for peptides have been more restrictive than necessary compared to other developed countries and pledged an HHS-wide review of the policies that govern peptide research and prescribing. These statements have shaped the tone of the policy debate even where they have not yet resulted in formal rulemaking.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.